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Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death
in the United States, due in part to the robust affinity of lung cancer cells to
metastasize. Understanding the processes that contribute to metastasis
provides promise for the discovery of novel therapeutic targets. Epithelial-tomesenchymal transition (EMT) is a proposed model for the initiation of
metastasis. During EMT cell adhesion and polarity is reduced, allowing epithelial
cancer cells to dissociate from the primary tumor and invade distant organs. The
transcription factor zinc finger E-box-binding homeobox 1 (ZEB1) has been
reported to uniquely correlate with NSCLC disease progression and to confer
therapy resistance in multiple tumor types. Additionally, depletion of ZEB1 has
been found to reverse therapy resistance, hence uncovering regulators of ZEB1
provides promise for innovative therapeutic strategies that may improve lung
cancer patient outcome. Recent publications demonstrate that ZEB1 undergoes
post-translational modification, suggesting a method for regulating ZEB1
function; however, the extent to which ZEB1 is modified as well as the purpose
of ZEB1 modification has not been fully elucidated. Here, we apply two
independent screens- BioID and an Epigenome shRNA dropout screen- to define
ZEB1 interactors that regulate post-translational modification and are critical to
metastatic NSCLC. These screens revealed an interaction amongst ZEB1 and
the histone deacetylase (HDAC)-containing nucleosome and deacetylase
remodeling complex (NuRD). Through treatment with class I HDAC inhibitors
Trichostatin A, we identified that ZEB1 homodimerizes and determine that
acetylation at lysine residue 811 regulates this association. Furthermore, we
identify the NuRD complex as a novel ZEB1 co-repressor and the Rab22 GTPase
activating protein TBC1D2b as a ZEB1/NuRD complex target. We find that
TBC1D2b suppresses E-cadherin internalization, thus hindering cancer cell
invasion and metastasis. Ultimately, this project provides a novel regulatory
node for ZEB1 function and insight to the role of EMT in endocytosis.
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CHAPTER 1:
Introduction

1

Lung cancer
Lung cancer is the leading cause of all cancer related death in the United States
and worldwide1. The two major types of lung cancer are non-small cell lung cancer
(NSCLC) and small cell lung cancer (SCLC)2. NSCLC constitutes approximately 85% of
lung cancers and is comprised of three subtypes: squamous cell carcinoma, large cell
carcinoma and the most common histologic type, adenocarcinoma. Poor patient prognosis
is primarily due to the affinity of tumors to metastasize leading to advanced disease at the
time of diagnosis2. Nearly two-thirds of lung cancer patients are diagnosed with metastatic
disease. Despite ongoing research the 5 year survival rate of lung cancer patients has
changed little in the last decade due in part to the incomplete understanding of the
metastatic process.
To study the biologic processes driving lung cancer progression, several
genetically engineered mouse models have been generated3. The somatic activation of
the KrasG12D allele (KrasLA1) was found to contribute to the development spontaneous lung
adenocarcinoma; however these models lacked metastatic potential4. Introduction of a
mutant p53 allele (p53R172H∆G)- commonly found in Li-Fraumeni syndrome patients- to the
KrasLA1 mouse model (denoted as KrasLA1p53R172HDG or KP mouse model) was found to
recapitulate features of metastasis-prone lung adenocarcinoma cancer patients. To
understand the molecular mechanisms driving metastatic disease our group derived a
panel of cell lines from the primary and various metastatic tumor sites of the KP model 4.
These cell lines were subcutaneously injected into syngeneic mice to evaluate the
propensity to metastasize. The cell line 393P (derived from primary lung tumor) was
defined as a metastasis incompetent cell line, 344SQ (subcutaneous metastasis) was a
metastasis prone cell line, and 393LN (lymph node metastasis) was capable of
2

intermediate metastasis- able to produce lung metastases when injected by tail vein or
intra-cardiac injection, but not subcutaneously.
Comparison of the transcriptional profiles of these models revealed differential
gene expression between metastatic and non-metastatic disease5. The genes associated
with tight junction and cell differentiation were down-regulated in the 344SQ tumor
compared to the 393P tumor. Based on these characteristics it was determined that the
344SQ mRNA profile was consistent with cells undergoing the biological process known
as epithelial-to-mesenchymal transition (EMT). During EMT epithelial cells lose apicalbasal polarity and specialized cell contacts to acquire migratory behavior6, 7. EMT is
integral to implantation and embryonic gastrulation, but aberrant activation of EMT is the
crucial mechanism for the initiation of cancer cell dissemination. EMT enables tumor cells
to disassociate from the epithelial cell layer and invade remote locations. Dissecting the
molecular mechanisms that regulate EMT has become critical for understanding tumor
invasiveness and metastasis.
Epithelial cell-cell contacts are maintained by three structures: tight junctions,
adherens junctions, and desmosomes 8. Adherens junctions initiate cell-cell contacts and
mediate the maintenance of the contact. Adherens junctions are a complex consisting of
the transmembrane protein E-cadherin and intracellular components, β-catenin and αcatenin. The extracellular domain of E-cadherin initiates the intercellular contact through
pairing with the trans-domain of E-cadherin on the opposing cell. Meanwhile, the Ecadherin cytoplasmic domain binds to β-catenin, which in turn binds α-catenin, tethering
the complex to the actin cytoskeleton. Seminal studies have demonstrated that loss of Ecadherin perturbs the formation of cell-cell contacts and promotes tumor progression
toward metastasis 9. Historically, E-cadherin down-regulation in cancer has principally
3

been attributed to two mechanisms (1) dysregulation of adherens complexes maintenance
and (2) epigenetic silencing or genomic loss of the E-cadherin locus.
Post-translational Regulation of E-cadherin
E-cadherin is dynamically endocytosed and relies on the recycling pathway for the
maintenance of homeostasis; however, these endocytic pathways are often dysregulated
in cancers and a shift in the balance can result in lysosomal mediated degradation and
increased cell migration. Endocytosis is the process by which cells internalize
macromolecules and surface proteins. The process is initiated when endocytic proteins
are surrounded by an area of plasma membrane, which buds off inside the cell to form a
vesicle containing the ingested cargo 10. Endocytosis occurs by several mechanisms that
can be divided into clathrin-dependent and clathrin-independent. In clathrin-dependent
endocytosis (CDE), the cytoplasmic domain of the plasma membrane is packaged into
clathrin-coated vesicles that are brought into the cell

11.

In contrast to CDE, clathrin-

independent endocytosis (CIE) comes in many forms, such as macropinocytosis and
phagocytosis 12. Cargo can be routed to late endosomes and lysosomes for degradation,
slowly recycled to the trans-Golgi network (TGN), or recycled to endosomal carriers that
rapidly bring the cargo back to the plasma membrane. Though the majority of studies
report clathrin-dependent endocytosis (CDE) for E-cadherin internalization, clathrinindependent endocytosis (CIE) have been implicated 13. Post-transcriptional mechanisms
have been shown to promote E-cadherin internalization and cell-cell dissociation

14.

For

example, upon v-Src expression E-cadherin can be ubiquitinated and shuttled to the
lysosome, displacing the normal recycling route 15.
Irrespective of the method of entry, Rab GTPases facilitate the endocytosis of
cargos and direct endosomes to a variety of intracellular pathways 16. The general function
4

of Rab GTPases depends on the dynamic GTP/GDP cycling for the assembly of multiprotein machinery. Belonging to the Ras superfamily of small GTPases, Rabs rely on
guanine-nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) to
catalyze the exchange and hydrolysis of GTP. Rab proteins interact with specific effectors
to both determine the cargo and the direction for vesicle movement. For example, Rab11
is responsible for the sorting of early endosomes for recycling through recruitment of the
effector FIP2, which connects vesicles with myosin Vb and promotes endosome
movement to the plasma membrane. While several Rabs have been intensively studied,
the function and regulation of many are still poorly understood. Recent discoveries have
implicated Rabs in several diseases such as the progression of multiple cancers

17, 18.

In

particular, specific Rabs can promote the membrane trafficking and degradation of cell
adhesion molecules, such as E-cadherin, thus encouraging the metastatic transformation
of tumor cells.
Transcriptional Regulation of E-cadherin
While germline mutations have been identified, methylation of the E-cadherin
promoter is a key event during metastasis. Multiple EMT-associated transcription factors
such as TWIST, SNAIL, SLUG, ZEB1 and ZEB2 19-21 mediate repression; however, in lung
adenocarcinoma zinc finger E-box binding homeobox 1 (ZEB1, δEF1, zfhx1a) expression
is an early and pivotal event in pathogenesis; conferring metastatic properties, treatment
resistance, and correlating with poor prognosis22. ZEB1 is a transcriptional repressor
characterized by a centrally located homeobox domain and two terminal flanking zinc
finger domains, which allow for E-box binding in the promoters of target genes (Fig. 1)23.
When ZEB1 was first identified as a repressor in the early 1990s, it was designated an
EMT-associated transcription factor due to the exclusive expression in mesodermal
5

tissues 24. Zeb1 null mice die perinatally, exhibiting severe T-cell deficiency of the thymus
and various skeletal defects 25. These developmental defects were coupled with increased
Figure 1: Diagram depicts protein structure of human ZEB1. The centrally located
homeobox domain (581-640) is flanked by two terminal zinc finger domains (240 to 277
and 918 to 971), which allow for E-box binding. Marked are the four post-translational
modifications that have previously been described: S585-phosphorylation; K347sumoylation; K774-sumoylation; K774 or K775-acetylation.

MET, as demonstrated by upregulation of E-cadherin -a central component in adherens
junctions. These findings underscored the critical role of ZEB1 in developmental EMT. The
function of ZEB1 in adult tissues is essentially still not well defined, though the ability of
ZEB1 to induce an EMT has implicated ZEB1 in the metastatic process.
ZEB1 orchestrates EMT through repression of epithelial genes such as E-cadherin
and the microRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429),
which is considered a master regulator of the epithelial phenotype5, 26-28. ZEB1 represses
transcription of target genes through the epigenetic regulation of promoter chromatin
architecture. Densely arranged heterochromatin regions restrict the access of the
transcription machinery thereby limiting the expression of the underlying gene. ZEB1
enhances heterochromatinization at target gene promoters by increasing H3K27
deacetylation and tri-methylation29. Class I and II HDAC inhibitors have been shown to
have efficacy in restoring ZEB1 target gene expression, but the mechanism behind this
association remains incomplete30. ZEB1 can interact with the C-terminal binding protein
(CtBP) corepressors, to aid in the recruitment of the CoREST complex in pancreatic
6

tumors31. However subsequent work has proposed that ZEB1 represses targets via CtBPindependent mechanisms in prostate cancer- suggesting that ZEB1 binding partners may
be context specific32. Understanding how ZEB1 functions provides promise for innovative
therapeutic strategies to improve lung cancer patient outcome.
Although ZEB1 has a predicted molecular weight of 125 kDa, multiple groups have
reported discrepancies in the observed molecular weight (approximately 190-220 kDa) 3335.

Some evidence attributes this molecular weight difference to post-translational

modification. For instance, in human cholangiocarcinoma cell lines the histone
acetyltransferases p300 and p/CAF were shown to acetylate ZEB1, resulting in inhibition
of ZEB1 function 35 (depicted in Fig. 1). Additionally, in radio-resistant breast cancer it has
been shown that ATM phosphorylates and stabilizes ZEB1 which in turn directly interacts
with USP7 and enhances its ability to deubiquitylate and stabilize CHK1, thereby
promoting homologous recombination-dependent DNA repair and resistance to radiation
36.

Yet no group has been able to account for the total discrepancy between the predicted

and observed molecular weight of ZEB1. Therefore, to identify ZEB1 interacting partners
and thereby better understand its biology and potential post-translational modifications,
we applied the biochemical BioID screening method.
BioID screening method
Identification of protein-protein interactions aids in deciphering the regulation and
function of complex biological pathways, providing insight into potential targetable
mechanisms for manipulation. Protein-protein interactions are classically identified
through isolation of protein complexes that interact with a bait by affinity purification and
identification by mass spectrometry (AP-MS). A recent publication described proximitydependent biotin identification (BioID), which is a refinement of AP-MS methodology
7

utilizing the biotin ligase mutant, BirA-R118G (BirA*) 37. The prokaryotic biotin ligase BirA
has stringent specificity for its substrate and can biotinylate molecular associations within
10 nm. The R118G mutation renders the enzyme promiscuous, therefore when fused to
a bait protein, BirA-R118G will biotinylate proteins proximal to the protein of interest. In
contrast to AP-MS, this methodology allows for the elucidation of transient or weak
interactions that may be lost during stringent lysis and wash phases. Subsequent to lysis,
biotinylated proteins were captured and purified using streptavidin conjugated beads and
identified by mass spectrometry analysis. The computational tool ‘significance analysis of
interactome’ (SAINT) was then applied to assign confidence scores to protein-protein
interactions and derive the probability of a bona fide protein-protein interaction. Application
of BioID revealed 77 ZEB1 interactors, of which 14 were previously published in ZEB1
AP-MS screens. Intriguingly, 13 identified members of the NuRD chromatin remodeling
complex were identified in the top 20 ranked ZEB1 interactors.
The NuRD complex is one of four major chromatin remodeling complexes, which
consists of at least six core subunits

38.

The complex is unique from other chromatin

remodeling complexes in that it contains two catalytic components: chromodomain
helicase DNA-binding proteins (CHD4/Mi-2β and CHD3/Mi-2α), which have ATPdependent chromatin remodeling activity and act as a scaffold for other members, and
histone deacetylases (HDAC1 and HDAC2), which catalyze protein deacetylation. The
other non-enzymatic subunits include GATAD2a (also known as p66α) and GATAD2b
(also known as p66β), retinoblastoma-binding proteins (RBBP4 and RBBP7), metastasisassociated gene proteins (MTA1, MTA2, and MTA3), and methyl-CpG binding domain
proteins (MBD2 and MBD3). The current understanding of the biochemical and structural
features of NuRD components suggests that combinatorial assembly of these factors

8

confers functional specificity of the NuRD complex. For instance, CHD3 and CHD4 are
found in mutually exclusive NuRD complexes with non-overlapping functions 39.
Multiple biological functions are regulated through NuRD chromatin modification
and post-translational modification of transcription factors. Alterations in NuRD activity
have been implicated in a broad range of human diseases, including cancer

40.

In

particular, the role of the MTA family members in the context of NuRD recruitment and
cancer development has emerged in recent years. Evidence has shown that the NuRD
complex associates with oncogenic transcription factors via the MTA family to promote
transcriptional repression 41. In addition to gene regulation, multiple groups have observed
the role of NuRD in post-translational modification of transcription factors 42. For example,
the NuRD complex can promote deacetylation of p53 to inhibit p53-dependent growth
arrest and apoptosis 43. Here we uncover ZEB1 acetylation contributes to dimerization and
propose a model in which the NuRD complex associates with ZEB1 to perform as a corepressor and deacetylate ZEB1 thus inhibiting dimerization.
Transcription factor dimerization
The dimerization of transcription factors is a common regulatory node governing
cell function 44. Heterodimerization affords functional diversity, whereas homodimerization
provides unique functions distinct from monomers. Several studies have suggested that
transcription factors originally functioned exclusively as monomers

45.

Presumably

evolutionary constraints resulted in the emergence of DNA-binding domains that bound
with less affinity, obligating transcription factors to diversify and function as dimers.
The best studied families that form dimers are bHLH, bZIP, NR, MADS-box, HDZIP and NF-kB families

46.

Members of these transcription factor families contain highly

conserved DNA-binding domains and less conserved dimerization domain. This is
9

frequently the case for zinc finger-containing transcription factors. Although most zinc
fingers appear to contribute to protein-DNA interactions, zinc fingers have also been
implicated in protein-protein interactions 47. Nonetheless, within several transcription factor
families, monomers can sufficiently function. Often the purpose of dimerization for these
transcription factors is to both increase specificity and affinity of binding.
The tumor suppressor transcription factor p53 was the first non-histone targets
identified to be acetylated

48.

p53 is acetylated at multiple lysine residues residing in the

C-terminal DNA binding regulatory domain, which serves to promote protein stability

49.

Since then there has been an explosion in the identification of acetylated non-histone
targets, particularly transcription factors. The functional consequence of protein
acetylation is variable, but aberrant modification can cause problems in cell signaling.
Accordingly, characterization of ZEB1 acetylation and dimerization may further reveal
functional and pathological relevance to metastatic disease.

10

CHAPTER 2:
Materials and Methods

11

Cell Culture
Human lung cancer cell lines H157, H1299 and H358 were obtained from the
National Cancer Institute (NCI-H series) or the Hamon Center for Therapeutic Oncology
Research, University of Texas Southwestern Medical Center (HCC series). Cell lines from
the KP mice were derived and maintained as previously described 4. Cell line names depict
the mouse number and site of derivation (e.g., 393P was derived from primary lung tumor).
HEK/293 Flp-In T-Rex cells were provided by the Raught laboratory (University of Toronto)
and were cultured in DMEM with 0.4% Hygromycin B. All other cell lines were cultured
and passaged in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and
incubated in 5% CO2 at 37°C. In separate experiments, cells were cultured for 4 hours in
the presence of hydroxychloroquine or MG-132.
BioID
Zeb1 was cloned from the pLenti-GIII-CMV-hZEB1-GFP-2A-Puro lentiviral vector
(Applied Biological Materials Inc., LV362466, Accession No. BC112392) using PCR
amplification with primers containing AscI and Not1 (N-terminus tag) or Kpn1 and NotI (Cterminus tag) restriction enzyme sites and cloned in to the pcDNA5 FRT/TO Flag-BirAR118G
(pcDNA5 Flag-BirA*). BioID was conducted as previously reported 50.
Primer name

Sequence 5' to 3'

Flag-BirA-ZEB1 Asc1 -F
Flag-BirA-ZEB1 NotI-R
ZEB1-BirA-Flag KpnI -F
ZEB1-BirA-Flag NotI-R

tataGGCGCGCCaATGgcggatggccccaggtg
ttaaGCGGCCGCaTCAggcttcatttgtctttt
tataGGTACCgccaccATGgcggatggccccaggtg
ttaaGCGGCCGCggtggcttcatttgtctttt

The N-terminus or C-terminus Flag-BirA tag vector control and Zeb1 were
transfected into HEK/293 Flp-In along with pOG44 Flp-Recombinase expression vector
using Lipofectamine® LTX Reagent with PLUS™ Reagent as per the manufacturer's
12

instructions (Invitrogen, Cat. No. 15338100). Cell lines were cultured until colonies were
~3 mm in diameter at before divided into two pools. These were considered as a biological
replicate and were processed independently.
Subsequently, all cell lines were cultured in four different conditions and harvested:
(1)
(2)
(3)
(4)

DMEM
DMEM + 5 μM MG-132
DMEM + 1 μg/ml Tetracyclin and 50 μM biotin
DMEM + 1 μg/ml Tetracyclin, 50 μM biotin, and 5 μM MG-132

Samples were snap-frozen and shipped on dry ice to the Raught laboratory for processing,
mass spectrometry, and analysis.
Epigenome Screen
Murine lung cancer cell lines (393P and 344P) were infected at a multiplicity-ofinfection (MOI) of 0.3 with a pooled shRNA lentiviral library targeting 235 epigenes (10
independent shRNAs/gene)

51.

The GEMM-derived cells were transplanted at 106 cells

per mouse ensuring an in vivo representation of 400 cells/barcode. Illumina base calls
were processed using CASAVA (v.1.8.2), and resulting reads were processed using our
in-house pipeline. Raw FASTQ files are filtered for a 4-bp spacer (CGAA) starting at 18th
base allowing for one mismatch, such that only reads amplified using above mentioned
PCRs are used for further processing. We then extract 23–40 bp of the above reads for
targeting libraries, and 1–18 bp for non-targeting library. These are further aligned using
Bowtie (2.0.2) to their respective libraries (2.4k mouse Epigenome and 12.5k nontargeting library) (Langmead et al., 2009). Then use SAMtools to count the number of
reads aligned to each barcode. Read counts are normalized for the amount of sequencing
reads retrieved for each sample, using library size normalization. Redundant shRNA
Activity (RSA) analysis method was employed to assign a p-value to a single gene relative

13

to the experimental effects

52.

Fold change distribution was calculated by comparing the

RSA value of the 344SQ to 393P.
Quantitative Real-Time PCR Analysis
Total RNA was extracted using TRIzol® Reagent (Life Technologies) and was
isolated according to the manufacturer's instructions. Analysis of mRNA levels was
performed on a 7500 Fast Real-Time PCR System (Applied Biosystems) with SYBR®
Green Real-Time PCR, using primers designed using the NIH primer design tool. The
ribosomal housekeeping gene L32 was used as an internal control and data was analyzed
with the 7500 Software v2.0.5 (Applied Biosystems). Analysis of microRNA levels was
performed using the TaqMan miR assays according to the manufacturer's instructions
(Applied Biosystems). All microRNA data are expressed relative to miR-16 performed
simultaneously on the same sample. Student’s t-test was performed for statistical
significance. For primer sequences see below.
Gene

qPCR Primer Sequence

KCNK1-F (ms)

TTCCAGGGGAAGGCTACAACCA

KCNK1-R (ms)

CTCGTGGAGTTCACAGAAGGTC

TBC1D2-F (ms)

CAGGAGAGGATGGAGCATCTGA

TBC1D2-R (ms)

ACTTGGTCAGCAGGGCTTTCTC

MUC1-F (ms)

AGTGCCTCTGACGTGAAGTCAC

MUC1-R (ms)

GGGAGGGAACTGCATCTCATTC

PTPN6-F (ms)

TTGGCAGGAGAACACTCGTGTC

PTPN6-R (ms)

TGCTCCCTACTGTTGGTCACAG

MACC1-F (ms)

TATTACAGCACGGCAAGGGC

MACC1-R (ms)

TTAGCTGCGTGATGTCCTCC

ATG4D-F (ms)

GTCTACATCGGCTAGTGGAGCT

ATG4D-R (ms)

GACTTCTGAGCAACTCTCCACAG

IFNGR1-F (ms)

CTTGAACCCTGTCGTATGCTGG

IFNGR1-R (ms)

TTGGTGCAGGAATCAGTCCAGG
14

EPS8L2-F (ms)

AGCCAGACAGTGCTAAACCAGC

EPS8L2-R (ms)

GAGCACTCTCAATGTCTTCCTGC

GADD45B-F (ms)

GGAGACATTGGGCACAACCGAA

GADD45B-R (ms)

CTGCTCTCTTCACAGTAACTGGC

DNM1-F (ms)

GTGGACATGGTTATCTCGGAGC

DNM1-R (ms)

GGTGGTCACAATTCGCTCCATC

FAM188A-F (ms)

CTCGGTATCCATGAACAAGCAGC

FAM188A-R (ms)

GTGAGTTTCGCTGCCAACAATCC

GTPBP2-F (ms)

GGACTGTGGTTGGAGGAACACT

GTPBP2-R (ms)

ACCTGCTCGAAGAACACGACAC

TERF2IP-F (ms)

GAGAACTCCAGATTTGCCTGAAG

TERF2IP-R (ms)

AATCAGGAGGGCTCTCATCCAC

SCAF8-F (ms)

AGACCTTCAACAGCGAGTTGTAT

SCAF8-R (ms)

CTTAATAGCTTTGATGGCTGCCT

PLLP-F (ms)

GTTTGTCGCTGTCTTCCTCTGG

PLLP-R (ms)

AGAGAACCGTGGCAGCGACAAA

MPC1-F (ms)

CTCCAGAGATTATCAGTGGGCG

MPC1-R (ms)

GAGCTACTTCGTTTGTTACATGGC

UBE2Q2-F (ms)

CAGGAAGACTCAAAGGCAAGACC

UBE2Q2-R (ms)

CCTGCCTTGTAGCTCTGTGATC

TBC1D2B-F (ms)

TGGAACTCTCGGCTCTACGAAG

TBC1D2B-R (ms)

TTCAACCTGGCAGAGCTTGGCT

FAM207A-F (ms)

TAGTGCGTTGGTGCAGAGGCTG

FAM207A-R (ms)

TGTAACCATCGCTCACGGCGAA

CHKA-F (ms)

TTGGCGATGAGCCTCGGAAAGT

CHKA-R (ms)

GTGACCTCTCTGCAAGAATGGC

TXNIP-F (ms)

GTTGCGTAGACTACTGGGTGAAG

TXNIP-R (ms)

CTCCTTTTTGGCAGACACTGGTG

FGFR1OP2-F (ms)

TCTCGGCACATCCTTGAAGCAC

FGFR1OP2-R (ms)

TGCTGCCATCTCGGTGATTTGG

KCTD5-F (ms)

TGCCAGTGAAGCATGTGTACCG

KCTD5-R (ms)

GTAAGAGGAGCCAATGCTGACC

IPMK-F (ms)

CTTCACTCTGACAGCTACGAGAC

IPMK-R (ms)

GAATACTGGCGGCAATCGCATC
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STXBP5-F (ms)

GCTGGTCATTCAGTTGGTGTGG

STXBP5-R (ms)

CTGGAGGTAGTCAACCATTGCG

MAN1A2-F (ms)

CGGTGGGTTTTCTGGTGTCAAG

MAN1A2-R (ms)

GGTAGAAGGTCATCGCCAGAGA

DIAPH3-F (ms)

TCAGCATCTCCTGCTCATTCGC

DIAPH3-R (ms)

GTGAAGTCAGGGTCCGTTCCAT

SH3GL1-F (ms)

AGTCAGAGGGTCTGTTGGGAGA

SH3GL1--R (ms)

CGATGTCCAGTGAGTCCTTCAC

CAB39L-F (ms)

CAGCAAGCCAGAGAACCTGAAAC

CAB39L-R (ms)

CTCCACGATAGGCTGCGTTTTG

CENPO-F (ms)

AAGATAGCCGCAGCACACCTAC

CENPO-R (ms)

CGTGAGGACATCGCAGAAGTCA

LEMD2-F (ms)

CTCTTCGAGGTTTAAGGCTGCG

LEMD2--R (ms)

CCACTTTGTCCACTGTAGTCGC

HAT1-F(ms)

GATGGAGCTACGCTCTTTGCGA

HAT1-R(ms)

GCCCTGACCTTGAAATGGAGTC

C1orf210-F(ms)

TCCTCTCCATTCTCATCGCGCT

C1orf210-R(ms)

AGGCTGGATGTAATTGTCCTCGA

msZeb1-F

ATGCTCTGAACGCGCAGC

msZeb1-R

AATCGGCGATCTTTGAGAGCT

msCDH1-F

CCATCTCAAGCTCGCGGATA

msCDH1-R

TCCAACGTGGTCACCTGGT

msCDH2-F

GCCATTGATGCGGATGATC

msCDH2-R

CCTGTACCGCAGCATTCCAT

msVimentin-F

TCCAAGCCTGACCTCACTGC

msVimentin-R

TTCATACTGCTGGCGCACAT

msRab22a-F

CAGCATTGTCGTTGCCATCGCA

msRab22a-R

CGCTGGTCTCTACAAAGATGGC

hsRab22a-F

GCACCAATGTACTATCGAGGGTC

hsRab22a-R

CATGCTGTCGAAGCTCTTTCACC

Immunoblot
Protein estimation was conducted by use of the Pierce™ BCA Protein Assay Kit
(Thermo Scientific, Cat. No. 23227). Samples were separated on SDS polyacrylamide
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gels and transferred onto a nitrocellulose membrane. The membranes were blocked using
5% nonfat dry milk and incubated in primary antibody overnight at 4oC (see Table 2 for
antibody list). Membranes were exposed using ECL (GE Healthcare) per the
manufacturer’s instructions.
Antibodies and Immunofluorescence
Cells were fixed with 4% paraformaldehyde, then permeabilized with 0.1% Triton
X-100. The slides were incubated with the primary antibodies overnight at 4 °C. DAPI for
the nuclear stain was contained in the mounting solution.
Protein

Company

Catalog No.

ZEB1

Santa Cruz, Cell Signaling

H-102, H-102X, 3396

normal mouse IgG

Santa Cruz

SC-2025

normal rabbit IgG

Santa Cruz

SC-2027

E-Cadherin

B&D

160182

Flag

Sigma

F1804

MTA1

Cell Signaling

5647

MTA2

Santa Cruz

Sc-9447

MTA3

Santa Cruz

81325

HDAC1

Cell Signaling

5356

HDAC2

Cell Signaling

5113

CHD3

Cell Signaling

4241

CHD4

Abcam

ab72418

GFP

Santa Cruz

sc-9996

Rab22

Santa Cruz

sc-390726

TBC1D2b

Santa Cruz

sc-398906

B-actin

Sigma

A1978

Proximity Ligation Assay
A total of 1 × 105 cells were seeded overnight onto glass coverslips. The next day,
cells were fixed, permeabilized, blocked with BSA, and probed with primary antibodies
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(listed above). Cells were then treated with Duolink In Situ Red Starter Mouse/Rabbit kit
(Sigma) as per manufacturer's instructions. Images were captured by confocal
fluorescence microscope (Nikon). Area of PLA signal was quantified in Adobe Photoshop
CC 2017 and graphs represent relative area of PLA signal per nuclear area; standard
deviation n=5.
Gel Filtration
Cells were washed twice with cold PBS, scraped, and collected by centrifugation
at 1500 g for 5 min. Nuclear proteins were extracted and protein concentration was
determined using BCA Pierce protein assay kit (Thermo Scientific). Protein was applied
to a Superose 6 size exclusion column (Amersham Biosciences) that had been
equilibrated with buffer and calibrated with protein standards. The column was eluted at a
flow rate of 0.4 ml/min, collecting 0.5 ml fractions. Fractions were analyzed by immunoblot
with various antibodies as indicated.
Immunoprecipitation
Pull-down assays were performed using 500 μg of crude lysate incubated
overnight with the primary antibody at 4◦C and gentle agitation. Protein A/G PLUS-Agarose
Immunoprecipitation Reagent (SC-2003) was then introduced for 2 h. Antibody-antigen
complexes were washed with phosphate-buffered saline (PBS) and Wash Buffer (50 mM
Tris (pH 7.4), 150 mM NaCl, 0.1% NP-40), eluted with 1 x RIPA buffer at 100 ͦC and
separated by SDS-PAGE before Western blot analysis.
RNA Interference
The human CHD4 siRNA SMARTpool was purchased from Dharmacon (L009774-00-0005) and used at a final concentration of 25 nM. siRNA transfection was
conducted using Lipofectamine RNAiMAX (Thermo Fisher Scientific). TRC Lentiviral
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pLKO.1 plasmid expressing scrambled control shRNA or murine TBC1D2b shRNA were
purchased from Dharmacon (TRCN0000106070, TRCN0000106071, TRCN0000106072,
TRCN0000106073, and TRCN0000106074). 344SQ and 531LN2 cells were virally
infected as previously described and stably selected through culturing in RPMI 1640 with
10% FBS and puromycin.
Luciferase Reporter Assays
For 3′UTR reporter assays cells were co-transfected with 5 ng of pRL-TK Renilla
plasmid (Promega) and 500 ng miR-200b∼200a∼429 promoter firefly luciferase reporter
plasmids using Lipofectamine 2000 (Invitrogen) 27. 24 hours after transfection, cells were
doxycycline induced for 24 to express GFP-ZEB1 or GFP vector only. For select
experiments cells were first pre-transfected for 24 hours with siRNA followed prior to cotransfection of reporter constructs, then assayed for luciferase activity after an additional
24 hours of doxycycline induction. All reporter assays were performed using the DualLuciferase reporter assay system (Promega, Madison, WI)
Chromatin Immunoprecipitation
Cells (1 × 107) were fixed in 1.1% formaldehyde for 10 min at room temperature
followed by quenching with 0.125 M glycine. Nuclei lysed were isolated as previously
described, and DNA was sheared by sonication to fragments of ∼300 bp

53.

Chromatin

was precipitated using the anti-ZEB1 (Santa Cruz) or anti-CHD4 antibody (Abcam). After
reversal of cross-links, precipitated DNA was subjected to qPCR analysis using genespecific primer pairs (see below).
Gene

ChIP Primer Sequence

miR‐200c,141- F

AGGGCTCACCAGGAAGTGT

miR‐200c,142- R

AGATCCCTGGCTCCCATC

TBC1D2-F(hs) #1

GAGACTGCGGAGGGACGAG
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TBC1D2-R(hs) #1

CCCAGGTGTCTCCCTTTGGG

TBC1D2-F(hs) #2

GGCAGCTTCCCAAAGGGAGA

TBC1D2-R(hs) #2

CGCCGTAACCTGGGTTTGC

TBC1D2-F(hs) #3

GAGACTGCGGAGGGACGAG

TBC1D2-R(hs) #3

CCCAGGTGTCTCCCTTTGGG

KCNK1-F(hs) #1

ACCTGCTGGTTCCCGTAACA

KCNK1-R(hs) #1

GTGAGGCCAAGAGAGGTGCT

KCNK1-F(hs) #2

TCCTGGTGCTGGGCTACTTG

KCNK1-R(hs) #2

GCACTCGTGCTCCTCCAAGA

KCNK1-F(hs) #3

GAGCACGAGTGCCTGTCTGA

KCNK1-R(hs) #3

GTTGCTGAGCACCGACACG

EPS8L2-F(hs) #1

GACGGAGGCTCCCAAGAAGG

EPS8L2-R(hs) #1

ACTCACGGCAGCACATGGA

EPS8L2-F(hs) #2

TAAGGGAAGTGACTCTGCCC

EPS8L2-R(hs) #2

AGGCCTCGAGCTCTTCCTT

EPS8L2-F(hs) #3

GGGGCTGCCACAAAGAAAA

EPS8L2-R(hs) #3

ACATACCTGCCCCAGGTGA

SEMA3F-pr ChIP- hs F

GGCGTATGGATGTGTGGATGA

SEMA3F-pr ChIP- hs R

TATGAGAGCACCCACCCAGAAC

SEMA3F-neg ChIP- hs F

CCCTACAGTTCCAGCAGCCC

SEMA3F-neg ChIP- hs R

CCACCAACCCAGACCCTGAT

DNM1-F(hs) ChIP

AGACCCAACCCATTGACAAA

DNM1-R(hs) ChIP

GGCATCATGGGTGTCGTAGT

PTPN6-F(hs) ChIP

TCCATTTACCTCCGCTGAAC

PTPN6-R(hs) ChIP

GATTCTCACCCTTTGCTTGC

TXNIP-F(hs) ChIP

CAGCCCCAAACCTGAAAGTA

TXNIP-R(hs) ChIP

AGAGCCTGTCGTTATTCCTG

PTPN6-F(hs) ChIP #2

GCTTGGGGTATGAAGGTTTG

PTPN6-R(hs) ChIP #2

CAGCGGAGGTAAATGGAAAA

TBC1D2b-F(hs) ChIP #1

GGGTCAGTTGCCTTCGTG

TBC1D2b-R(hs) ChIP #1

GAAATAGACCATTGCTTCATCC

TBC1D2b-F(hs) ChIP #2

GCCCTGGTAGCTGAAGCA

TBC1D2b-R(hs) ChIP #2

CGCCGCTGCTACCTTTACT
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Migration and Invasion Assay
Cells were resuspended in serum-free media and seeded in a 24-well Transwell
or Matrigel plate (BD Biosciences) at a concentration of 5 x 104 per well. RPMI
supplemented with 10% FBS was added to the lower chamber and cells were allowed to
migrate for 16 h in 5% CO2 at 37°C. Migrating cells were stained with 0.1% crystal violet.
Non-migrating cells were removed using a cotton swab. Migrated cells were quantified
based on five microscopic fields at a 4X magnification and results were represented as
mean ± standard deviation and student’s t-test was performed for statistical significance.
Each assay was performed in triplicate.
Biotin Internalization Assay
Following doxycycline induction for 4 hours, cells were washed with PBS
containing 10mM CaCl2 and 1mM MgCl2 and incubated with 0.5 mg/ml EZ-Link NHS-SS
Biotin (Pierce) for 30 min on ice, followed by washing with quenching reagent (15mM
glycine in PBS-Ca2+-Mg2+). Old media was added and cells were incubated at 37°C for
various time points to allow endocytosis. Biotinylated proteins at the plasma membrane
were then stripped at 0°C by glutathione treatment twice for 15min (60mM glutathione,
75mM NaCl, 10mM EDTA, 75mM NaOH and 1% BSA). Cells were lysed (1% Triton X100, 150mM NaCl, 50mM Hepes pH 7.6 with protease inhibitors as above) and an aliquot
was separated to measure total amount of E-cadherin. Biotinylated proteins (internalized)
were recovered from lysates by immunoprecipitation with streptavidin beads. The amount
of internalized and total E-cadherin was quantified by Western blots.
In vivo tumor and metastasis experiments
All animal experiments were reviewed and approved by the Institutional Animal
Care and Use Committee at The University of Texas M.D. Anderson Cancer Center. Cells
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were subcutaneously injected in the flanks of syngeneic 129/Sv mice of 8–10 weeks age
and observed for tumor growth for a period of 5 weeks. Upon euthanasia, metastatic
nodules on the surface of lung lobes were counted manually. Lung tissue was fixed in
10% formalin and then processed for sectioning followed by haematoxylin and eosin
staining.
3D Culture
Cells were grown in 8-well chamber slides coated with Matrigel (BD 356231) or
Matrigel/Collagen (BD 354249, 1.75 mg/ml type I Collagen concentration), as previously
described 5. The media (RPMI with 10 % FBS and 2 % Matrigel) was replaced daily and
supplemented with doxycycline. The morphology of the structures was monitored every 2
days by light microscope.
Lambda Phosphatase incubation
Cells were lysed with 1 x NEBuffer for PMP supplemented with 1 mM MnCl2 or
with 1 X RIPA Buffer (Cell Signaling 9806). Lysates harvested in the PMP buffer (30 μg)
was treated with 400 units of lambda-phosphatase/20 μL for 30 min. at 37 ͦ C. Samples
were immediately separated on an SDS polyacrylamide gel and transferred onto a
nitrocellulose membrane.
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Metastasis in Lung Cancer
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BioID screen reveals ZEB1 interactome
Previous studies have applied affinity purification-mass spectrometry (AP-MS)
analysis to identify proteins in stable association with ZEB1

33, 54;

however, a high-

confidence ZEB1 protein interactome has yet to be established. To elucidate ZEB1
transcriptional co-regulators we applied the BioID screening method to identify ZEB1
interacting partners 37, 55. This technique harnesses an abortive E. coli biotin ligase (BirAR118, denoted BirA*) fused to a protein of interest. BirA* can generate biotinoyl-AMP, but
has lost the ability to interact with this intermediate. Highly reactive biotinoyl-AMP is thus
released into the vicinity of the bait protein, and reacts with amine groups on nearby
polypeptides. Biotinylated proteins can then be isolated with streptavidin and identified
using mass spectrometry. In contrast to traditional AP-MS, this methodology allows for the
elucidation of interactions that may be lost during stringent lysis and washing (Fig. 2A).
A FlagBirA* tag was fused in-frame to either the N- or C-terminus of human ZEB1 and
stably integrated into HEK293 Flp-In cells, under the control of a tetracycline-inducible
promoter. Two isogenic pools were generated for each bait protein, representing biological
replicates. We performed RT-qPCR and immunoblot to validate ZEB1 upregulation and to
determine the effect on the expression of the known ZEB1 target gene, E-cadherin. Upon
tetracycline induction, exogenous expression of ZEB1 consistently produced E-cadherin
repression by both mRNA and protein expression (Fig. 2B and 1C). To additionally assess
the functionality of the FlagBirA*-tagged human ZEB1 proteins, we expressed the
constructs in the murine 393P cell line (Fig. 3A). Both tagged ZEB1 constructs significantly
upregulated the migratory and invasive potential of the 393P cell line, confirming that the
FlagBirA* tag did not hinder the biologic function of ZEB1 (Fig. 3B). The expression of
FlagBirA* protein alone (denoted as “-“) had no effect on E-cadherin expression levels or
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Figure 2: (A) Human Zeb1 was cloned into the pcDNA5-FlagBirA*-FRT/TO vector.
Fusion of an E coli abortive biotin ligase mutant (BirA*) to ZEB1 allows for biotinylation
of ZEB1 proximal proteins. Biotinylated proteins are captured by streptavidin
conjugated sepharose beads and identified by mass spectrometry to define the ZEB1
interactome. Constructs retained biological activity as assessed by repression of the
established ZEB1 target, E-cadherin (cdh1) by (B) transcription and (C) protein
expression.
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Figure 3: (A) 393P cells were pre-transfected with siRNA control or siRNA targeting
murine ZEB1 (denoted mZEB1), prior to transfection with FlagBirA*, FlagBirA*-hZEB1
(human ZEB1) or hZEB1-FlagBirA*. Relative mRNA confirms mZEB1 knockdown and
hZEB1 overexpression. (B) Transwell assays was conducted to determine whether
fusion constructs can functionally replace endogenous ZEB1.
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invasive potential in these assays.
Following validation of the biological activity of the N- and C-terminal tagged ZEB1
proteins, cell pools were incubated with tetracycline, biotin and the proteasome inhibitor
MG-132. Biotinylated proteins were isolated with streptavidin-sepharose beads, washed,
and subjected to trypsin proteolysis. The released peptides were identified using nanoflow
liquid chromatography–electrospray ionization–tandem mass spectrometry (nLC–ESI–
MS/MS). Using cells expressing the FlagBirA* tag alone for comparison, the computational
tool Significance Analysis of INTeractome56 was used to assign confidence scores to
individual protein-protein interactions with ZEB1. Proteins confidently identified with a Max
SAINT score > 0.8, identified with > 2 unique spectra in both analyses, and with at least
2.5-fold greater peptide counts in the FlagBirA*-ZEB1 samples than in FlagBirA* samples,
yielded a high-confidence list of 68 ZEB1 interacting proteins (Table 1). Notably, BioID
identified a novel association between ZEB1 and several HDAC1 and HDAC2 containing
co-repressor complexes: Sin3, CoREST, and the NuRD complex. In fact, all core
members of the NuRD complex were identified as the top-ranking hits in the BioID screen.
Several members of the NuRD complex were previously identified as ZEB1 interactors
(Fig. 4).
Loss-of-function screen identifies vulnerabilities in NSCLC
To ascertain the significance of these ZEB1 interactors as therapeutic targets in
metastatic NSCLC we utilized a previously published in vivo shRNA drop out screen
methodology specifically concentrated on epigenetic regulators51. ZEB1-mediated
epigenetic dysregulation is documented in metastatic NSCLC and a variety of cancer
types, implying a causal role in disease pathogenesis. To differentiate epigenetic
vulnerabilities between metastatic and non-metastatic NSCLC, we enlisted two murine cell
27

Table 1: High confidence FlagBirA*-ZEB1 interactors. MS data were analyzed as
described in the text. Proteins identified with a max SAINT score > 0.8, proteins
identified with > 2 unique peptides and with spectral counts at least 2.5-fold higher
in FlagBirA*-ZEB1 samples are shown. NuRD complex members are highlighted in
blue.
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Figure 4: Venn diagram depicts comparison of BioID interactors to other AP/MS
studies, Zhang et al. 2013 and Gubelman et al. Overlap of the high-confidence BioID
ZEB1 interactors identified all known members of the nucleosome remodeling and
deacetylase (NuRD; also known as Mi-2) complex as bona fide ZEB1 interacting
partners.
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line models derived from the genetically engineered KrasLA1/+;p53R172H∆G/+ (KP) mice4, 5.
We have previously described the KP model to faithfully recapitulate features of metastatic
lung cancer patients. Aimed at understanding the drivers of metastatic disease our group
derived a panel of lung adenocarcinoma cell lines from the KP model. Subcutaneous
injection of the KP cell lines into syngeneic mice established the cell line 393P to be an
epithelial and non-metastatic phenotype, while the cell line 344P is mesenchymal and has
metastatic ability 4.
A barcoded shRNA library, previously published by Carugo et. al., targeting 235
unique epigenetic regulators was infected into 393P and 344P cells

51.

Target regulators

included subunits of various complexes that remodel nucleosomes, catalyze posttranslational modifications, deposit histone variants and methylate DNA. To enhance the
robustness of the screen and facilitate hit prioritization, the library was designed with ten
unique shRNAs targeting each gene. To ensure adequate representation of the complexity
of the deep-coverage shRNA library in mouse samples, mice were implanted with 400
cells/shRNA. Tumors were harvested at 150-200 mm3 and barcode abundance was
quantified by sequencing (In Vivo). The cell lines grown in vitro (In Vitro) were also
sequenced to potentially delineate genes that contribute to in vivo survival (Fig. 5). To
detect the top “hits” (or top scoring genes) emerging from the screens, we assigned pvalues from RSA (Redundant shRNA Activity) scores. Comparison of the RSA values of
344P (mesenchymal) and 393P (epithelial) allowed for the identification of genes which
are essential for growth of the mesenchymal metastatic model vs the epithelial and nonmetastatic model. The top 15% of most differentially regulated genes were compared to
the BioID screen and yielded five genes: CHD3, CHD4, CHD5, CHD8, and MTA3. One of
the most robust hits to emerge by both in vitro and in vivo screening was CHD4, which
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Figure 5: Depiction of the Epigenome short hairpin RNA (shRNA) dropout screen.
Briefly, (1) an shRNA library consisting of 235 unique mouse or human epigenetic
regulators was infected in to the murine Kras/p53 lung cancer cell lines, 393P and 344P.
(2) Syngeneic 129/Sv mice were implanted with 400 cells/shRNA and monitored for
four weeks; (3) Tumors (denoted “In Vivo”) and cell lines (denoted “In Vitro”) were
sequenced to determine the barcoded shRNAs abundance.
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Figure 6: Differential analysis of 344P and 393P RSA score reveals hits with the most
significant rank change. Graphs represents top fifteenth percentile in in vitro and in vivo
analysis. Cross analysis with BioID indicates that knockdown of the NuRD complex
members CHD4 and CHD3 significantly impaired in vitro and tumor growth in 344P but
had little effect on 393P.
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was also the most significant interactor in the BioID screen, suggesting the NuRD complex
is central to the biology of mesenchymal NSCLC (Fig. 6).
ZEB1 interacts with the NuRD complex
To validate the ZEB1-NuRD interaction we employed co-immunoprecipitation (coIP) in the HEK293 Flp-In cells originally utilized to conduct the BioID screen. Upon
FlagBirA*-ZEB1 immunoprecipitation we were able to co-IP HDAC1 and through
immunoprecipitation of MTA1 we observed co-IP of ZEB1 (Fig. 7A-7C). Furthermore,
using exogenously expressed GFP-conjugated ZEB1 in the 344SQ murine cell line, we
were also able to detect an interaction between ZEB1 and the NuRD complex members
HDAC1 and MTA1 by co-IP (Fig. 7B). We next explored the endogenous interaction of
ZEB1 with each member of the NuRD complex through the application of the proximity
ligation assay (PLA). The PLA technique employs oligonucleotide labeled species-specific
secondary antibodies, which when within close proximity (30-40 nm) allow the
oligonucleotides to be ligated for amplification of the resulting circular DNA. The amplified
signal may then be visualized by the use of fluorescently-labeled oligonucleotides and
fluorescence microscopy. Addition of the ZEB1 or HDAC1 specific antibodies alone
yielded only background levels of fluorescence in H157 cells. However, focal nuclear
fluorescence signals were detected when cells were probed with both the ZEB1 and
HDAC1 antibodies (Fig. 8). Similar results were observed for HDAC2, CHD4, MTA1,
MTA2, and MTA3 in the human and murine NSCLC cell lines H157 (Fig. 9A), H1299 (Fig.
9B), 344SQ (Fig. 9C), and 531LN2 (Fig. 9D), providing additional evidence that ZEB1
interacts with the NuRD complex. Considering that the MTA family of proteins form
mutually exclusive NuRD complexes, frequently with non-overlapping function

41,

we

found it interesting that PLA detected an interaction with all MTA members. Given that the
CHD
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proteins also form exclusive complexes, we noted that ZEB1 preferentially forms a
complex with CHD4/NuRD in NSCLC cell lines.
To further substantiate the observation that ZEB1 interacts with the NuRD
complex, human H157 and murine 344SQ lung cancer cell lines were utilized to conduct
gel chromatography. We determined the apparent molecular weight of ZEB1 by applying
nuclear lysates to a Superose column. The eluate was collected in 60 sequential fractions
of equal volume and analyzed by SDS-PAGE, followed by immunoblotting for ZEB1.
Native ZEB1 from both H157 (Fig. 10A) and 344SQ (Fig. 10B) cells eluted with an
apparent molecular mass much greater than that of the predicted mass (125 kDa). ZEB1
immunoreactivity was detected in chromatographic fractions from the Superose column in
one distinct peak greater than 669 kDa. Significantly, the elution pattern of ZEB1
overlapped with that of the NuRD complex proteins HDAC1 and CHD4, further supporting
the finding that ZEB1 interacts with the NuRD complex.
The CHD4-containing NuRD complex is a ZEB1 co-repressor
Previously, ZEB1 was found to recruit class I and II HDACs in pituitary
organogenesis through the formation of a complex containing CtBP and the CoREST
corepressors 57. However, our discovery implicated the NuRD complex in ZEB1-mediated
repression. In order to explore the significance of the physical association between ZEB1
and the NuRD complex, we analyzed established transcriptional targets of ZEB1 by
chromatin IP (ChIP). Since the chromodomain helicase DNA binding proteins CHD3 and
CHD4 participate in distinct forms of the NuRD complex and given our observation that
ZEB1 interacts predominantly with CHD4 in NSCLC, we designated CHD4 as a surrogate
for the NuRD complex. In these experiments, ChIP was performed in H1299 cells with
antibodies against ZEB1, CHD4, and H3K27ac. This modification was selected following
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previous studies, which suggested the CHD4/NuRD complex specifically demethylates
H3K27 to recruit the Polycomb Repressive Complex 2 (PRC2) 58. We additionally depleted
CHD4 to understand the significance of the NuRD complex to the regulation of the
promoter activity of established ZEB1 genes. We selected miR-200c and SEMA3F as
established ZEB1 target genes and included the CHD4/NuRD regulated gene, N-Myc, and
SEMA3F intron 13 to be a negative control for ZEB1 binding

29, 30, 59.

Upon depletion of

CHD4 we observed reduced CHD4 binding at all of the loci queried (Fig. 11A-11B). We
detected ZEB1 and CHD4 at the promoter of miR-200c and SEMA3F, but ZEB1 did not
localize to the N-Myc promoter or SEMA3F intron 13 (Fig. 11C). We observed that ZEB1
binding to both the miR-200c and SEMA3F promoters was increased upon knockdown of
CHD4. Yet, despite this increase in ZEB1 binding we observed an increase of H3K27ac
at each of the CHD4 co-localized regions, suggesting that ZEB1 was not capable of
repressing these genes in the absence of CHD4/NuRD recruitment (Fig. 11D).
To determine whether ZEB1 can orchestrate CHD4/NuRD recruitment we
expressed a doxycycline inducible GFP-ZEB1 in the human NSCLC cell line H358 (H358GFP-ZEB1). Upon ZEB1 expression we observed a phenotypic EMT, which was
confirmed by down-regulation of E-cadherin (Fig. 12A). We subsequently performed ChIP
for CHD4 and ZEB1. Consistent with the BioID and phenotypic data, we detected cobinding of ZEB1 and CHD4 at the miR-200c-141 and SEMA3F promoters only in the ZEB1
overexpressing cells, suggesting that ZEB1 enhances CHD4-NuRD binding at these sites
(Fig. 12B and 12C). By contrast we found CHD4 binding at the N-Myc promoter was not
influenced by ZEB1 overexpression and we did not find ZEB1 binding to the SEMA3F
intronic region under either circumstance.
We also utilized the H358-GFP-ZEB1 cell line to ascertain the significance of
CHD4 in the ZEB1-dependent repression of the miR-200a-b-429 cluster. We performed a
38
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luciferase reporter assay, using the luciferase coding region cloned downstream of the
miR-200a-b-429 promoter 60 and transfected into the H358_GFP or H358_GFP-ZEB1
cells prior to doxycycline induction for 24h (Fig. 13A). As expected, induction of ZEB1
expression decreased the luciferase reporter activity as compared to the GFP control
(Fig. 13B). To determine whether ZEB1 was capable of repressing the miR-200a-b-429
promoter expression in the absence of CHD4, we transiently knocked down CHD4 prior
to expression of ZEB1. In the ZEB1 expressing cells we observed a rescue of the
luciferase activity upon CHD4 knockdown, suggesting that ZEB1 regulates miR-200
expression through a CHD4/NuRD complex. Consistent with these results, the
endogenous gene expression of miR-200b and miR141 was similarly restored upon
CHD4 depletion (Fig. 13C).
Identifying targets of a ZEB1/NuRD complex
We postulated that defining ZEB1/NuRD target genes may uncover regulatory
pathways contributing to NSCLC invasion and metastasis. To delineate direct
transcriptional effectors of this complex we utilized the ZEB1 and CHD4 ChIP-seq data
provided by the ENCODE project (Encyclopedia of DNA Elements)61 (Fig. 14).
Overlapping DNA sequences/gene promoters were considered potential targets of a
ZEB1/CHD4/NuRD complex, and identified a total of 7231 different genomic locations. We
further filtered this list by analysis of several mRNA datasets to identify targets that are
inversely correlated with ZEB1 expression. Datasets included comparison of ZEB1
overexpression in the 393P murine cells, miR-200 overexpression in murine 344SQ cells,
ZEB1 knockdown in human MDA-MB-231 breast cancer cells, and ZEB1 overexpression
in 3T3-L1 pre-adipocytes 5, 54, 62. 93 candidates were repressed by at least 50% upon ZEB1
overexpression in the 393P cell line and were significantly changed in any other one
dataset. Our last criterion was the location of the binding site in relation to the distance
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from the transcription start site, as ZEB1 has been reported to preferentially bind gene
proximal regions (-/+ 250 bp from the TSS) 63. This yielded 37 genes, which we sought to
further validate (Table 2). We determined the capacity of ZEB1 to repress candidate
targets by comparing the mRNA expression of each gene upon constitutive ZEB1
overexpression in the 393P cell line (pcDNA_ZEB1; Fig. 15A and 15B) or inducible
expression of miR-200a-b-429 in the 344SQ cell line, which should rescue the target gene
expression (Fig. 16A and 16B). The potential target genes were stratified by fold change.
Genes that were repressed by 50% or more upon ZEB1 overexpression or increased by
2-fold upon ZEB1 suppression were considered candidate ZEB1/CHD4/NuRD target
genes. This yielded five genes: KCNK1, TBC1D2a, EPS8L2, DNM1, and TBC1D2b.
Additional analysis of the upstream promoter sequence of the candidate target genes also
revealed at least one E-box, in particular ‘CACCTG’, a previously described ZEB1 binding
motif 64.
We verified whether ZEB1 and CHD4 bind to the candidate target gene promoters
by employing ChIP in H1299 cells (Fig. 17). Compared to the non-specific control (IgG),
ZEB1 and CHD4 co-occupied the promoters of KCNK1, EPS8L2, TBC1D2a and
TBC1D2b, four of the five genes queried. To validate ZEB1 and CHD4 binding to the target
promoters, CHD4 was depleted by siRNA prior to ChIP with antibodies against ZEB1,
CHD4, and H3K27ac. CHD4/NuRD depletion resulted in marked reduction of the
recruitment of CHD4 to the promoter of EPS8L2, TBC1D2a, and TBC1D2b, but not
KCNK1, suggesting non-specific binding to the KCNK1 promoter (Fig. 18A). No
observable trend in ZEB1 binding was perceived upon CHD4 knockdown (Fig. 18B),
however H3K27 acetylation increased at the TBC1D2a, TBC1D2b, and EPS8L2
promoters, signifying these were indeed targets of a CHD4/NuRD complex (Fig. 18C). To
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delineate whether ZEB1 could enhance CHD4 binding to these two target promoters we
again utilized the H358-GFP-ZEB1 cell line. Inducible ZEB1 expression produced a
significant recruitment of CHD4 to the TBC1D2a, TBC1D2b and EPS8L2 promoters
compared to vector control cells (Fig. 19A and 19B).
TBC1D2b/Rab22 axis mediate E-cadherin endocytosis
Preliminary experiments transiently overexpressing each of the three hits yielded
from the analysis of the ENCODE ChIP-seq data (Fig. 20A and 20B) suggested that all
three genes significantly affect in vitro migration and invasive potential of murine NSCLC
(Fig. 20C); however, TBC1D2b posed an intriguing candidate. Previous work has revealed
TBC1D2b as a GTPase activating protein (GAP) for Rab22 family members (Rab22 and
Rab31) 65. Both Rabs are described in sorting recycling endosomes; however, Rab22 was
recently identified in the membrane trafficking of clathrin-independent endosomes.
Additionally, Rab22 has previously shown to be required for lung cancer cell migration and
invasion

66.

To study the role of TBC1D2b in lung cancer metastasis we inducibly

expressed TBC1D2b or GFP in the murine and human cell lines 344SQ, 531LN2 and
H1299. These cell lines exhibited a robust upregulation of TBC1D2b mRNA (Fig. 21A)
and protein expression (Fig. 21B) upon doxycycline induction. This observation was
further confirmed by immunofluorescent staining, which revealed TBC1D2b localization to
the cytoplasm (Fig. 21C). We also observed a physical association between TBC1D2b
and Rab22 by co-IP, but could not detect an interaction with Rab31 (Fig. 22). We next
investigated the functional role of TBC1D2b in tumor cell migration and invasion.
Overexpression significantly reduced Transwell migration and invasion, as well as
migration in a wound closure assay (Fig. 23A and Fig. 23B). Conversely, stable TBC1D2b
knockdown increased both Transwell migration and invasion (Fig. 24A and 24B). To
determine whether this phenotype was due to the TBC1D2b/Rab22 association we
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expressed a GFP-conjugated human Rab22 in 393P, H358 and H1299. Again, upon
doxycycline induction we witnessed upregulation of Rab22 mRNA and protein expression
(Fig. 25A and Fig. 25B). Rab22 overexpression significantly upregulated Transwell
migration and invasion (Fig. 25C), a phenotype previously observed by other groups

63.

To determine if TBC1D2b could avert this invasive phenotype we performed a rescue
experiment in which TBC1D2b was transiently overexpressed in GFP-Rab22-expressing
cells. After 24h of TBC1D2b expression doxycycline was utilized to induce expression of
Rab22 for 12 h. Subsequently, cells were harvested to confirm expression (Fig. 26A) and
to perform Transwell migration and invasion assays. The cell line 393P has limited ability
to migrate and thus we observed no significant difference upon TBC1D2b overexpression
in the GFP control cells in either assay. However, in the Rab22 overexpressing cell line,
TBC1D2b expression suppressed the migratory and invasive phenotype despite an
increase in Rab22 transcriptional levels, suggesting that TBC1D2b hinders invasion
through the regulation of Rab22 protein activity (Fig. 26B).
Interested in the significance of TBC1D2b expression in the context of EMT and
metastasis, we also examined E-cadherin levels. Although there was no significant effect
on E-cadherin transcription upon TBC1D2b manipulation until 24h of induction (Fig. 27A
and 27B), an increase in E-cadherin protein levels was observed within 4h of TBC1D2b
expression (Fig. 27C). Additionally, a faster migrating form of E-cadherin (97 kDa
compared to the commonly observed 120 kDa) was detected by immunoblot upon
TBC1D2b expression. E-cadherin dephosphorylation is a precursor to internalization

14,

and the accumulation of a lower molecular weight E-cadherin suggested that E-cadherin
was no longer endocytosed. Treatment of 344SQ-TBC1D2b lysate with lambda
phosphatase produced a molecular weight shift comparable to 97 kDa (Fig. 27D),
advocating that TBC1D2b promotes the dephosphorylated E-cadherin. Upon induction of
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Rab22 overexpression in 393P we also observed degradation productions of E-cadherin
at approximately 35 kDa, suggesting that Rab22 promoted E-cadherin degradation (Fig.
28A). We found that treatment with the lysosomal inhibitor hydroxychloroquine (HCQ) was
able to prevent E-cadherin degradation, while a proteosomal inhibitor (MG-132) did not,
signifying that Rab22 promotes E-cadherin lysosomal degradation (Fig. 28B). To
determine if TBC1D2b plays a significant role in the regulation of E-cadherin degradation
we co-expressed GFP-E-cadherin67 and RFP-LAMP1 in the 344SQ_TBC1D2b
knockdown cell lines to determine the fate of E-cadherin by live cell imaging. We observed
the GFP-E-cadherin localized to the cell periphery in wildtype control cells, while in the
TBC1D2b knockdown cells we observed co-localization of the GFP and RFP signals,
suggesting that the absence of TBC1D2b directs E-cadherin to the lysosomal
compartment for degradation (Fig. 28C). To determine whether TBC1D2b was regulating
surface E-cadherin uptake we performed a biotin internalization assay (Fig. 29A and 29B).
TBC1D2b was expressed for 6 hours prior to labeling surface proteins with cleavable
biotin. Cells were then incubated at 37°C for up to 1h to allow protein internalization and
surface biotin was cleaved to determine the relative amount of E-cadherin that was
endocytosed. Compared with control cells, a reduced amount of biotinylated E-cadherin
localized to the cytoplasm of TBC1D2b overexpressing 344SQ and 531LN2 murine lung
cancer cells, suggesting that TBC1D2b regulates E-cadherin endocytic processing. Of
note, the total amount of E-cadherin remained unchanged in both TBC1D2b and GFP
control cell lines. Conversely, Rab22 overexpression significantly contributed to the uptake
of E-cadherin in the cell line 393P over 24h (Fig. 30).
TBC1D2b hinders NSCLC metastasis
To determine the potency of TBC1D2b in metastasis in vivo, we implanted
syngeneic mice subcutaneously with the TBC1D2b overexpressing or control 344SQ cells.
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Despite no difference in primary tumor growth, we observed a ~6-fold decrease in the
number of distant lung metastatic nodules after 5 weeks (Fig. 31A and 31B). This was
confirmed by haematoxylin and eosin staining of lung sections (Fig. 31C). Further analysis
of TBC1D2b overexpressing tumors also confirmed an increase in TBC1D2b expression,
which corresponded with an increase in E-cadherin mRNA and protein (Fig. 32A and 32B).
Conversely, we observed no significant difference in primary tumor size when comparing
the growth of 344SQ tumors with constitutive TBC1D2b knockdown to the non-targeting
control group (Fig. 33A and Fig. 33B), but an increased number of metastatic lesions were
detected, again support the hypothesis that TBC1D2b is a potent metastasis suppressor.
Haematoxylin and eosin staining of lung sections confirmed the increased metastasis
observed from gross examination (Fig. 33C). TBC1D2b knockdown contributed to
downregulation of E-cadherin expression (Fig. 34A and 34B)
Based on our overall findings we propose a model in which ZEB1 and CHD4/NuRD
work in concert to repress TBC1D2b as well as other targets such as the miR-200 family
(Fig. 35). TBC1D2b down-regulation results in an increase in Rab22 activation and in turn
promotes E-cadherin internalization and degradation, enhancing in vivo metastasis.
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CHAPTER 4:
ZEB1 acetylation precludes
homodimerization

72

Class I HDAC inhibitors regulate ZEB1 dimerization
To determine whether the enzymatic activity of the NuRD complex members
HDAC1 and HDAC2 contribute to ZEB1 mediated repression we utilized the class I HDAC
inhibitors Mocetinostat and Trichostatin A (TSA). Previous reports have found that use of
these inhibitors can induce mesenchymal-epithelial transition (MET) by repressing ZEB1
expression, subsequently restoring the transcription of targets such as the miR-200 family
30.

Treatment with TSA for 24h did not significantly affect ZEB1 transcription (Fig. 36A).

Although we did find that 48h of treatment did down regulate ZEB1 expression (data not
shown). We concurrently found that utilization of these inhibitors caused the molecular
weight of ZEB1 to shift from ~250 kDa to 125 kDa (Fig. 36B and 36C). The predicted
molecular weight of ZEB1 is 125 kDa, but a growing body of evidence indicates that ZEB1
appears as two species-125 kDa and 190-250 kDa.
Given that the observed molecular weight difference is twice that of ZEB1
predicted molecular weight we questioned whether ZEB1 was forming a homodimer. To
assess this hypothesis we co-transfected a GFP-ZEB1 and a flag-ZEB1 in the 344SQ cell
line (Fig. 37A). Cells were treated with doxycycline to induce the expression of GFP,
GFP/Flag-ZEB1,

GFP-ZEB1,

or

GFP-ZEB1/Flag-ZEB1

for

24

h

and

co-

immunoprecipitation was conducted with an anti-GFP antibody (Fig. 37B). Immunoblot for
flag antibody indicated that GFP-ZEB1 co-immunoprecipitated with flag-ZEB1,
demonstrating that ZEB1 forms a homodimer that is not disrupted by SDS-PAGE reducing
conditions. Additionally, this suggested that class I HDACs are responsible for the
maintenance of ZEB1 dimerization.
We noted that after 24h of TSA treatment in the human cell line H1299 we could
induce a significant proportion of the total protein to appear as a monomer. We therefore
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performed chIP for ZEB1 to determine the capacity of ZEB1 to bind to the miR-200c and
SEMA3F promoter (Fig. 38A). Unlike knockdown of CHD4 which caused an increase in
ZEB1 binding, treatment with TSA caused ZEB1 binding to decrease at all of the queried
binding sites. An increase in H3K27ac was also observed, consistent with previous reports
(Fig. 38B).
ZEB1 dimerization is regulated by acetylation
We next questioned how class I HDACs dictated ZEB1 dimerization. Our data
indicated that ZEB1 acetylation may modulate homodimerization, therefore we decided to
perform tandem-mass spectrometry to identify post-translational modifications (PTMs).
Through utilization of a GFP conjugated murine ZEB1 in the 344SQ cell line we initially
confirmed that both observed bands (125 kDa and 250 kDa) are indeed ZEB1 (data not
shown). We then conducted mass spectrometry on peptides generated from both trypsin
or chymotrypsin digest to identify differences in phosphorylation, ubiquitination, and
acetylation. We were able to detect four phosphorylation sites (T131, Y577/Y578, S624,
and S657) and one acetylation site (K811) (Fig. 39A). None of these sites have previously
been identified and we noted that the Y577/Y578 site was located within the homeobox
domain (Fig. 39B).
To determine whether phosphorylation contributes to ZEB1 dimerization we
utilized lambda phosphatase, which has dual activity to sites of serine/threonine and
tyrosine phosphorylation. Both murine (393P and 344SQ; Fig. 40A) and human (H441,
H358, H1299, and H157; Fig. 40B) NSCLC cell lines were harvested in Protein
MetalloPhosphatases (PMP) buffer or in buffer containing phosphatase inhibitors as a
control. Lysates were incubated with lambda phosphatase for 30 min prior to immunoblot
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for ZEB1 and the total phospho-Ser/Thr antibody to determine the effectiveness of
treatment. A modest decrease in ZEB1 molecular weight was observed in the
phosphatase treated samples (~10 kDa in the murine cell lines and ~20 kDa in the human
cell lines), confirming that the protein is phosphorylated, but suggesting that
phosphorylation does not contribute to dimerization. Further experiments must be
performed to determine the functional significance of ZEB1 phosphorylation.
We then generated mutations of the single acetylation site identified by mass
spectrometry (mus musculus K811 or homo sapien K833). To mimic acetylation, we
exchanged lysine 811 with glutamine (K811Q) to model both the charge and chemical
structure of acetylated lysine. To abolish acetylation at this residue while conserving the
positive charge we mutated lysine to arginine (K811R). Overexpression of each ZEB1
mutant as a fusion protein with GFP in the 393P cell line demonstrated localization to the
nucleus, consistent with overexpression of wild-type ZEB1 (Fig. 41A). We observed
overexpression after 24h doxycycline induction both by qPCR and noted both mutants
repressed the expression of E-cadherin (Fig. 41B). Counterintuitively, immunoblot
indicated that the acetyl-mimetic mutant, ZEB1_K811Q, did not disrupt ZEB1 dimerization
(Fig. 42A). However, acetyl-deficient mutant ZEB1_K811R appeared exclusively at 125
kDa suggesting that disruption of acetylation hindered dimerization (Fig. 42B). To
determine whether the K811R mutant precludes dimerization, we co-expressed the GFPZEB1_K811R and flag-ZEB1_WT (Fig. 43A) in the cell line 344SQ. Immunoprecipitation
of the GFP-tagged mutant was unable to co-immunoprecipitate the wild type flag-ZEB1,
validating that acetylation is necessary for ZEB1 dimerization.
To assess the functional effect of ZEB1 deacetylation on tumor cell invasion we
performed Transwell migration and invasion assays. Both mutants were capable of
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promoting migration (Fig. 44A) and invasion (Fig. 44B) in Boyden chamber assays,
comparable to wild type ZEB1 overexpression. We next investigated tumor cell invasion
in 3D cultures. To model the extracellular matrix composition found in tumors, cells were
grown on a Matrigel/ collagen type I (1.75 mg/ml) mixture to reveal the differential 3D
organization. Control 344SQ cells grew as non-invasive colonies, but upon ZEB1 (wild
type) expression colonies displayed an invasive response, forming elongated protrusions
(Fig. 44C). 3D culture of the ZEB1 dimerization mutant ZEB1_K811R produced poorly
cohesive structures with protrusions appearing more rounded. Additional studies are
necessary to determine how monomer ZEB1 modulates cell invasion distinct of dimer
ZEB1.

84

85

CHAPTER 5:
Discussion
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The dysregulation of ZEB1 expression is associated with poor clinical prognosis in
numerous epithelial cancers and notably drives EMT in lung cancer pathogenesis

22.

Previous work has shown that ZEB1 cofactors are critical to its function in tumorigenesis,
metastasis, and therapy resistance

23.

Therefore we studied the molecular mechanisms

governing ZEB1 function in metastatic NSCLC by applying two independent screens, the
biochemical BioID screen

55

and an in vivo shRNA-mediated loss-of-function screen51.

This allowed us to study ZEB1 interactors that can be exploited therapeutically in
metastatic NSCLC. Here we report that ZEB1 interacts with the NuRD complex and that
chromodomain helicase family members are essential to the survival of metastatic
NSCLC. Multiple studies have demonstrated that the NuRD complex associates with other
transcriptional repressors, including FOG-1 68, and ZEB2 (Zfhx1b) 42, 69, 70. Previous ZEB1
affinity purification studies have detected an interaction between ZEB1 and some NuRD
complex members, although none followed up in studying the NuRD complex as a ZEB1
co-repressor 33, 71. To define the functional consequence of this interaction we considered
established targets of ZEB1 and determined that not only does ZEB1 recruit CHD4/NuRD
to target promoters, but in the case of miR-200, CHD4 is necessary to facilitate ZEB1mediated repression. Aberrant DNA methylation of the miR-200c/141 promoter is closely
linked to inappropriate silencing in cancer cells 72.
Interested in the identification of other ZEB1/CHD4/NuRD targets, we interrogated
the ENCODE ChIP-seq data and through application of stringent criteria defined the
paralogues TBC1D2a (Armus) and TBC1D2b as target genes. Rather than examining
Armus, which was previously described as a Rac1 effector and a bona fide GAP for Rab7
73, 74,

we selected to characterize TBC1D2b (mKIAA1055) due to its association with lung

cancer oncogenesis

75.

Earlier work established TBC1D2b as a Rab22 binding protein-

Rab22 (Rab22a) and Rab31 (Rab22b)

65.

TBC1D2b consists of two coiled‐coil (CC)
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domains, which are flanked by an N‐terminal pleckstrin homology (PH) domain and a C‐
terminal Tre‐2/Bub2/Cdc16 (TBC) domain. Truncation mutants of each domain
unexpectedly demonstrated that TBC1D2b has nominal GAP activity towards Rab22,
more likely serving as a hub for the recruitment of other Rab22 GAPs

65.

Studies now

place Rab22 at the level of recycling of clathrin-mediated endocytosis (CME) and clathrinindependent endocytosis cargo proteins 66, 76, 77. There have been other reports of Rab22
acting at endocytic entry points, markedly in the endocytosis of the TrkA receptor

77

and

in the early uptake of the bacterium Borrelia 78.
Initial overexpression of TBC1D2b led us to observe an upregulation and altered
electrophoretic mobility of E-cadherin. It is well established that the cytoplasmic tail of Ecadherin is phosphorylated in the β-catenin binding region, increasing its affinity for βcatenin14.

Additionally,

phospho-deficient

E-cadherin

mutants

exhibit

enhanced

endocytosis and degradation through a lysosomal compartment. Together with the
observed mobility shift we became intrigued by the role of TBC1D2b/Rab22 in the
regulation of E-cadherin uptake. E-cadherin degradation is efficiently blocked by the
expression of TBC1D2b, providing another important regulatory node for E-cadherin
turnover and stability of cell-cell contacts. A wealth of reports have demonstrated that
EMT-associated transcription factors bind to the E-box within the E-cadherin promoter to
suppress gene expression79; however, we provide evidence that ZEB1 can dually facilitate
the down-regulation of surface E-cadherin by promoting excessive internalization and
degradation. Our data also suggests that ZEB1 promotes hyper-activation of Rab22 and
may regulate other junctional proteins, thereby disrupting tissue polarity and instigating a
motile phenotype. Future studies will be required to determine whether ZEB1 influences
the activity of Rab7 through regulation of TBC1D2a during normal development and tumor
metastasis.
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Concurrently, we determined that TBC1D2b is an inhibitor of invasion in vitro and
metastasis in vivo. Given the physiological role of E-cadherin in cell-cell contacts, we
propose that TBC1D2b likely stabilizes the cell junctions found in epithelial cells.
Additionally, we find that TBC1D2b rescues Rab22-mediated cell migration and invasion.
Distinguishing the role of ZEB1-mediated Rab22 activation in the regulation of the
endocytic pathway is an important area for future investigation. Furthermore, endocytosis
entails selective packaging of cell surface proteins such as receptors that are frequently
skewed in cancer cells 80. Unveiling Rab22 cargo may yield invaluable tools for decoding
therapeutic resistance in multiple epithelial tumors.
In addition to our findings relating ZEB1 to increased endocytic uptake of cargo
such as E-cadherin, we are also the first group to identify ZEB1 homodimerization.
Previous work has suggested that class I HDAC inhibitors are a potent inducer of MET
through regulation of ZEB1 transcription thus restoring target genes such as the miR-200
family. However, our data suggested that these inhibitors could impede the NuRD complex
activity consequently stunting ZEB1 function. We therefore treated multiple NSCLC cell
lines with class I HDAC inhibitors and unexpectedly found that we could induce a dramatic
change in the molecular weight of ZEB1. Through co-immunoprecipitation studies we
demonstrated that ZEB1 forms a homodimer that depends on class I HDAC activity.
We performed mass spectrometry to identify PTMs which can regulate ZEB1
dimerization. Mass spectrometry of the dimer identified four novel phosphorylation sites
and one acetylation site, but did not identify any modifications on the monomer. Further
analysis must be conducted to increase the coverage and potentially identify other
modifications. To determine whether these phosphorylation modifications contribute to
ZEB1 dimerization we applied lambda phosphatase and found that we could not achieve
the disassociation of the dimer compared to application of TSA. Previous research has
89

suggested that ZEB1 phosphorylation contributes to protein stability

33,

however, further

research is necessary to determine the significance of the other PTMs unearthed in this
study.
We generated the acetylation mimetic and deficient ZEB1_K811 mutants and as
hypothesized, affecting this site hindered the ability of ZEB1 to homodimerize as assessed
by the inability to co-immunoprecipitate the wild type flag-ZEB1 with the mutant
ZEB1_K811R. Interestingly, this mutant was still capable of inducing an EMT, although
we provide evidence that the monomer is not capable of binding to the promoter of miR200c/141 or SEMA3F. We also noted that both the dimer and monomer eluted in fractions
larger than 669 kDa by column chromatography, suggesting that the monomer also
interacts with multi-molecular complexes. Furthermore, in 3D invasion assays the 344SQZEB1_K811R formed invasive spheres which appeared rounded as compared to the
elongated ZEB1 wild type overexpressing spheres. Tumor cells exhibit two distinct modes
of migration when invading the 3D microenvironment: mesenchymal or amoeboid 81. This
work suggests that ZEB1 monomer may modulate genes which contribute to an amoeboid
pattern of invasion. Further characterization is necessary to confirm if the ZEB1 monomer
and dimer differentially regulate gene expression.
ZEB1 ablation is associated with increased therapy sensitivity and underscores
the importance of ZEB1 as a crucial driver of tumor progression. Transcription factor
dimerization can facilitate enhancement of DNA-binding specificity and can become an
additional point of regulation. Recently, the disruption of transcription factor dimerization
has emerged as a novel and promising strategy for developing a new generation of drugs
44.

So far generation of dominant-negative peptides lacking the DNA-binding domain can

disrupt endogenous dimerization

82.

Together, our results suggest that this strategy of
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treatment with a cell penetrating dominant-negative form of ZEB1 may hold promise for
cancer therapy, either alone or in a multi-targeting approach.
In conclusion, our results unveil the oncogenic function of the NuRD complex in
NSCLC metastasis through physical association with and recruitment by ZEB1. The
ZEB1/CHD4/NuRD complex is responsible for mediating repression of miR-200c/141 and
TBC1D2b, a regulator of Rab22 and a potent suppressor of NSCLC invasion and
metastasis. These findings are the first to demonstrate how EMT associated transcription
factors

regulate

the

degradation

of

E-cadherin

protein

and

suggests

that

ZEB1/CHD4/NuRD can harness endocytosis to promote oncogenic signals. We also
uncover ZEB1 homodimerization and identify the site K811 as a pivotal regulator of
dimerization. Therefore, this data validates the targeting of the ZEB1 axis for the treatment
of metastatic lung cancer.
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CHAPTER 6:
Future directions
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Over the last decade, early diagnosis and targeted therapy has done little to
improve the survival rates of NSCLC patients. Moreover, despite the recent progress with
immunotherapy and approval of tyrosine kinase inhibitors as first-line therapy, EMT
remains a prominent mechanism of resistance- underscoring the need for further research
of this process. Since the identification of ZEB1 in the early 1990s if has been defined as
a transcriptional mediator of EMT and compared to other EMT-associated transcription
factors, ZEB1 is uniquely correlated with disease progression in NSCLC2. While
considerable research has focused on understanding the processes ZEB1 regulates, the
goal of this project was to uncover how ZEB1 functions. Through two unbiased screens,
we identify the NuRD complex as a ZEB1 interactor, necessary for the survival of
mesenchymal NSCLC. We propose a model in which the NuRD complex is dually a ZEB1
co-repressor and a regulator of ZEB1 dimerization.
In Chapter 4 we identify three ZEB1/NuRD target genes: EPS8L2, TBC1D2a and
TBC1D2b. Though we selected to study TBC1D2b, the other two pose as interesting
targets and the significance of these genes in metastasis has yet to be defined. EPS8L2
is a member of the SOS1/ABI1 multi-molecular complex which is required for Rac1
activation and actin cytoskeletal remodeling83. Intriguingly, TBC1D2a is also a Rac1
effector- coordinating between Rac1 and Rab7 during starvation74. Rab7 designates the
maturation of endosomes and autophagosomes, directing the trafficking of cargos along
microtubules, and finally, participating in the fusion step with lysosomes. Rac1 is part of
the Rho family of small GTPases, which are activated in a sequential manner to mediate
cell motility. In this model Cdc42 induces filopodia, Rac1 induces lamellipodia and
subsequently activation of Rho induces stress fiber formation, with Rho and Rac acting
antagonistically84, 85. Several reports show an association between autophagy and the
function of the Rho family. In particular, RhoA and Rac1 have a regulatory function on
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starvation-mediated autophagy, but with opposing roles86. RhoA activates autophagy,
while Rac1 inhibits autophagy. This implies that ZEB1 represses Rac1 activity to promote
autophagy progression. Autophagy and EMT are linked in a multifaceted relationship.
Given the numerous challenges that metastatic tumor cells overcome to successfully
establish distant colonies, cells that undergo EMT require autophagy activation to survive
during metastatic spreading. Accordingly, our data suggesting ZEB1 stimulates autophagy
substantiates these reports, but whether ZEB1 would inhibit Rac1 activation to achieve
this goal should be addressed in future work.
In this chapter we also propose that ZEB1 harnesses the endocytic circuitry by
repressing TBC1D2a and TBC1D2b. In addition to junction stability, key cellular processes
are regulated through dynamic endocytosis. To ascertain precisely which cargo are
influenced by ZEB1, mass spectrometry based vacuolar proteomics and lipidomics must
be performed. However, several cell surface proteins pose as interesting targets for future
work. Frequently receptor tyrosine kinases (RTKs) are aberrantly trafficked in lung cancer
and are often increased activity of endocytic molecules can prolong propagation of RTK
signals or mislocalize RTKs87. Similarly, whether ZEB1 regulates the recycling of MHCs
should be explored. Tumor cells evade immune recognition directly by downregulating
features that make them vulnerable such as tumor antigens or MHC class I. Tumors in
patients treated with anti-PD-1 who initially responded and then relapse showed loss in
MHC class I surface expression to avoid cytotoxic T cell recognition88. Previous work has
demonstrated that Rab22 plays a central role in the MHC class I endocytic trafficking and
silencing of Rab22 expression can drastically reduce the intracellular pool and recycling
of MHC class I molecules89. Future work should determine whether ZEB1 regulation of the
TBC1D2b/Rab22 axis could contribute to downregulation of MHC class I presentation and
immunotherapy resistance.
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Later in an effort to determine if HDAC inhibitors can restore ZEB1 target gene
expression we uncover that ZEB1 dimerizes. We additionally identify that dimerization is
prohibited through mutation of lysine 811 to arginine (ZEB1_K811R), which prevents
acetylation at this site. Much work remains to comprehend the phenotype produced by
expression of the monomer ZEB1, but we have noted a unique phenotype in 3D assays.
ZEB1_K811R formed invasive spheres, which appear rounded as compared to the
elongated ZEB1 wild type overexpressing spheres. There remain two explanations for this
observation. Previous work by our group has demonstrated that ZEB1 monomer has a
lower half-life compared to dimer ZEB1 (data not shown). Thus the reduced invasive
phenotype may be due to decreased protein expression. Future work studying the half-life
of the ZEB1_K811 acetylation mutants may provide more insights in to the contribution of
the NuRD complex to protein stability. Alternatively, our data may indicate that ZEB1
monomer modulates pathways which contribute to an amoeboid-type invasion. Previous
work has shown that ZEB1 is crucial for amoeboid-type invasion in breast cancer and has
demonstrated that RhoA activation is preferentially required for amoeboid invasion,
opposing Rac1 activation which drives cancer mesenchymal-type invasion90. Combined
with our data from Chapter 4, this again suggests that ZEB1 promotes Rac1 deactivation.
Additionally, this also indicates that the monomer regulates genes independent of the
dimer and may still associate with the NuRD complex. ChIP-seq and RNA-seq comparing
the monomer (ZEB1_K811R) to wild-type and dimer (ZEB1_K811Q) are necessary to
determine whether ZEB1 dimerization attributes to differences in signaling pathways.
Finally,

we

propose

that

ZEB1/NuRD

association

dually

facilitates

heterochromatinization of target gene promoters subsequent to deacetylation of ZEB1 to
disrupt dimerization. Mutation of lysine 811 to arginine prohibited ZEB1 from dimerizing
signifying that acetylation is necessary dimerization. We also establish that upon TSA
95

treatment of NSCLC lines ZEB1 binding is significantly decreased, while knockdown of
CHD4 enhances ZEB1 binding. Interestingly, knockdown of CHD4 did not achieve ablation
of ZEB1 dimerization but does contribute to upregulation of expression (data not shown).
Coupled, this data suggests that the monomer is unable to bind DNA as efficiently as the
dimer and that the NuRD complex hampers ZEB1 expression. Future work ought to
explore how the NuRD complex directly regulates ZEB1 and how HDAC activity affects
ZEB1 dimerization separate from the NuRD complex. Additionally, this may provide
insights to the molecular mechanisms underlying the response to HDAC inhibitors, which
are currently used in combination with other chemotherapeutic agents in multiple clinical
trials.
To date, we remain far from understanding the complex intracellular and
extracellular networks regulating the expression and function of ZEB1; however,
answering these questions may elucidate several of these mechanisms. In addition to
these questions, future work should also address how ZEB1 is involved in other disease
models such as Fuch’s endothelial dystrophy, where ZEB1 mutations frequently contribute
to disease progression; and how ZEB1 functions are altered in cancer in the context of
accumulating genetic alterations and the changing tumor environment. To this end,
investing in advance and intelligent experimental designs, particularly ChIP-seq analysis,
to reveal DNA binding and co-factor binding patterns for our ZEB1 dimer mutants may
provide impactful knowledge and extend our therapeutic strategies for NSCLC patients.
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